Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

BACKGROUND: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robin L., Ratain, Mark J., O’Dwyer, Peter J., Siu, Lillian L., Jassem, Jacek, Medioni, Jacques, DeJonge, Maja, Rudin, Charles, Sawyer, Michael, Khayat, David, Awada, Ahmad, de Vos-Geelen, Judith M.P.G.M., Evans, T.R. Jeffry, Obel, Jennifer, Brockstein, Bruce, DeGreve, Jacques, Baurain, Jean-Francois, Maki, Robert, D’Adamo, David, Dickson, Mark, Undevia, Samir, Geary, David, Janisch, Linda, Bedard, Philippe L., Razak, Albiruni R. Abdul, Kristeleit, Rebecca, Vitfell-Rasmussen, Joanna, Walters, Ian, Kaye, Stan B., Schwartz, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852771/
https://www.ncbi.nlm.nih.gov/pubmed/31522033
http://dx.doi.org/10.1016/j.ejca.2019.07.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852771/
https://www.ncbi.nlm.nih.gov/pubmed/31522033
http://dx.doi.org/10.1016/j.ejca.2019.07.024

Ejemplares similares